Major Estimate Revision • Aug 07
Consensus revenue estimates increase by 35% The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from US$11.1m to US$14.9m. EPS estimate unchanged from US$0.004 at last update. Chemicals industry in Indonesia expected to see average net income growth of 33% next year. Consensus price target broadly unchanged at Rp2,553. Share price rose 4.6% to Rp1,930 over the past week. New Risk • Aug 01
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.4% Last year net profit margin: 13% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.8x net interest cover). Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.4% net profit margin). Reported Earnings • Aug 01
Second quarter 2026 earnings released: EPS: US$0.001 (vs US$0.006 in 2Q 2025) Second quarter 2026 results: EPS: US$0.001 (down from US$0.006 in 2Q 2025). Revenue: US$3.12b (up 27% from 2Q 2025). Net income: US$100.0m (down 81% from 2Q 2025). Profit margin: 3.2% (down from 21% in 2Q 2025). Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in Indonesia. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Jun 30
PT Barito Pacific Tbk announces Annual dividend, payable on July 29, 2026 PT Barito Pacific Tbk announced Annual dividend of IDR 1.6300 per share payable on July 29, 2026, ex-date on July 06, 2026 and record date on July 07, 2026. Valuation Update With 7 Day Price Move • Jun 30
Investor sentiment deteriorates as stock falls 23% After last week's 23% share price decline to Rp1,285, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 17x in the Chemicals industry in Indonesia. Total returns to shareholders of 69% over the past three years. Major Estimate Revision • Jun 10
Consensus revenue estimates decrease by 12% The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from US$16.7m to US$14.7m. EPS estimate unchanged from US$0.0039 per share at last update. Chemicals industry in Indonesia expected to see average net income growth of 0.2% next year. Consensus price target broadly unchanged at Rp2,559. Share price was steady at Rp1,760 over the past week. Valuation Update With 7 Day Price Move • May 22
Investor sentiment deteriorates as stock falls 23% After last week's 23% share price decline to Rp1,605, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 12x in the Chemicals industry in Indonesia. Total returns to shareholders of 108% over the past three years. Tillkännagivande • May 20
PT Barito Pacific Tbk, Annual General Meeting, Jun 25, 2026 PT Barito Pacific Tbk, Annual General Meeting, Jun 25, 2026. New Risk • May 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indonesian stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (4.0% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings are forecast to decline by an average of 15% per year for the foreseeable future. Minor Risk Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Apr 30
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to Rp1,835, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 28x in the Chemicals industry in Indonesia. Total returns to shareholders of 127% over the past three years. Major Estimate Revision • Apr 16
Consensus revenue estimates increase by 47% The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from US$11.5m to US$16.9m. EPS estimate unchanged from US$0.0028 at last update. Chemicals industry in Indonesia expected to see average net income growth of 0.3% next year. Consensus price target up from Rp2,448 to Rp2,514. Share price rose 21% to Rp2,240 over the past week. New Risk • Apr 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indonesian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (4.0% operating cash flow to total debt). Earnings are forecast to decline by an average of 33% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to Rp1,765, the stock trades at a forward P/E ratio of 66x. Average forward P/E is 21x in the Chemicals industry in Indonesia. Total returns to shareholders of 127% over the past three years. Major Estimate Revision • Apr 07
Consensus revenue estimates increase by 21% The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from US$9.61m to US$11.6m. EPS estimate reaffirmed at US$0.0016. Net income forecast to shrink 68% next year vs 5.7% growth forecast for Chemicals industry in Indonesia . Consensus price target broadly unchanged at Rp2,451. Share price rose 7.0% to Rp1,460 over the past week. Reported Earnings • Apr 01
Full year 2025 earnings released: EPS: US$0.005 (vs US$0.001 in FY 2024) Full year 2025 results: EPS: US$0.005 (up from US$0.001 in FY 2024). Revenue: US$7.63b (up 220% from FY 2024). Net income: US$489.8m (up US$433.3m from FY 2024). Profit margin: 6.4% (up from 2.4% in FY 2024). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 3.8% growth forecast for the Chemicals industry in Indonesia. Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Mar 02
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to Rp1,810, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 21x in the Chemicals industry in Asia. Total returns to shareholders of 127% over the past three years. Tillkännagivande • Feb 04
PT Barito Pacific Tbk (IDX:BRPT) announces an Equity Buyback for IDR 1,000,000 million worth of its shares. PT Barito Pacific Tbk (IDX:BRPT) announces a share repurchase program. Under the plan, the company will repurchase up to IDR 1,000,000 million worth of its shares. The program will be fully funded by internal cash balance. The purpose of the program is to provide flexibility to achieve an efficient capital structure and reflect the Company's performance through the company's share price. Repurchased shares will be held as treasury shares and transferred within 3 years of completion. The program will expire on May 3, 2026. Recent Insider Transactions • Feb 02
President Commissioner recently bought Rp8.6b worth of stock On the 29th of January, Prajogo Pangestu bought around 4m shares on-market at roughly Rp2,150 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth Rp13b. Insiders have collectively bought Rp35b more in shares than they have sold in the last 12 months. Major Estimate Revision • Jan 31
Consensus revenue estimates decrease by 13% The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from US$9.77m to US$8.46m. EPS estimate unchanged from US$0.0058 per share at last update. Chemicals industry in Indonesia expected to see average net income growth of 30% next year. Consensus price target of Rp2,445 unchanged from last update. Share price fell 17% to Rp2,160 over the past week. Valuation Update With 7 Day Price Move • Jan 28
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to Rp2,300, the stock trades at a forward P/E ratio of 54x. Average forward P/E is 20x in the Chemicals industry in Asia. Total returns to shareholders of 180% over the past three years. Recent Insider Transactions • Jan 21
President Commissioner recently bought Rp8.5b worth of stock On the 15th of January, Prajogo Pangestu bought around 3m shares on-market at roughly Rp2,830 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought Rp42b more in shares than they have sold in the last 12 months. Price Target Changed • Jan 19
Price target increased by 52% to Rp2,445 Up from Rp1,604, the current price target is an average from 3 analysts. New target price is 17% below last closing price of Rp2,950. Stock is up 214% over the past year. The company is forecast to post earnings per share of US$0.0031 for next year compared to US$0.0006 last year. Major Estimate Revision • Nov 22
Consensus EPS estimates fall by 46% The consensus outlook for fiscal year 2025 has been updated. 2025 consensus EPS estimate fell from US$0.0065 to US$0.0035. Revenue forecast reaffirmed at US$8.64m. Net income forecast to shrink 63% next year vs 31% growth forecast for Chemicals industry in Indonesia . Consensus price target broadly unchanged at Rp1,605. Share price fell 7.7% to Rp3,490 over the past week. New Risk • Nov 04
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 2,016% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.2x net interest cover). Earnings are forecast to decline by an average of 45% per year for the foreseeable future. Minor Risk Large one-off items impacting financial results. Reported Earnings • Nov 04
Third quarter 2025 earnings released: EPS: US$0 (vs US$0 in 3Q 2024) Third quarter 2025 results: EPS: US$0 (in line with 3Q 2024). Revenue: US$2.34b (up 351% from 3Q 2024). Net income: US$42.3m (up US$50.0m from 3Q 2024). Profit margin: 1.8% (up from net loss in 3Q 2024). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in Asia. Over the last 3 years on average, earnings per share has increased by 129% per year but the company’s share price has only increased by 64% per year, which means it is significantly lagging earnings growth. Board Change • Oct 24
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 3 highly experienced directors. No independent directors (4 non-independent directors). Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Tillkännagivande • May 14
PT Barito Pacific Tbk, Annual General Meeting, Jun 19, 2025 PT Barito Pacific Tbk, Annual General Meeting, Jun 19, 2025. Location: jakarta Indonesia Tillkännagivande • Apr 25
PT Buana Primatama Niaga and PT Chandra Daya Investasi agreed to acquire PT Barito Investa Prima from PT Barito Pacific Tbk (IDX:BRPT) and PT Griya Idola for IDR 90 billion. PT Buana Primatama Niaga and PT Chandra Daya Investasi agreed to acquire PT Barito Investa Prima from PT Barito Pacific Tbk (IDX:BRPT) and PT Griya Idola for IDR 90 billion on April 21, 2025. A cash consideration of IDR 90 billion will be paid by PT Buana Primatama Niaga and PT Chandra Daya Investasi for 20,390 shares. The composition of BIP's share ownership after the share acquisition has changed. CDI is now the majority shareholder in BIP, namely 20,399 shares worth IDR 20.39 billion (99.99%). The remaining 1 share (1%) or worth IDR 1 million is owned by BPN. In order to support this transformation, BRPT and GI intend to transfer all share ownership in BIP to the CAP Group and its affiliates, namely BIP and BPN, so that the logistics business line can be more focused on being developed by the CAP Group. The object of this affiliate transaction is all shares owned by BRPT and all shares owned by GI in BIP with a total of 20,400 shares or representing 100% of all shares issued in BIP. The value of this transaction is recorded at IDR 90 billion.
Kantor Jasa Penilai Publik Syarif, Endang & Partners acted as fairness opinion provider for PT Barito Pacific Tbk. Reported Earnings • Nov 02
Third quarter 2024 earnings released: EPS: US$0 (vs US$0 in 3Q 2023) Third quarter 2024 results: EPS: US$0 (in line with 3Q 2023). Revenue: US$517.9m (down 30% from 3Q 2023). Net loss: US$7.69m (down 240% from profit in 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Chemicals industry in Indonesia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance. Recent Insider Transactions • Sep 04
Vice President Director recently bought Rp55m worth of stock On the 29th of August, Rudy Suparman bought around 45k shares on-market at roughly Rp1,220 per share. This transaction amounted to 8.9% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Rudy's only on-market trade for the last 12 months. Reported Earnings • Aug 01
Second quarter 2024 earnings released: EPS: US$0 (vs US$0 in 2Q 2023) Second quarter 2024 results: EPS: US$0 (in line with 2Q 2023). Revenue: US$540.6m (down 25% from 2Q 2023). Net income: US$25.6m (up 262% from 2Q 2023). Profit margin: 4.7% (up from 1.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 3.5% growth forecast for the Chemicals industry in Indonesia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance. New Risk • Jul 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indonesian stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.4x net interest cover). Share price has been highly volatile over the past 3 months (13% average weekly change). Tillkännagivande • May 12
PT Barito Pacific Tbk, Annual General Meeting, Jun 14, 2024 PT Barito Pacific Tbk, Annual General Meeting, Jun 14, 2024. Price Target Changed • May 11
Price target decreased by 27% to Rp845 Down from Rp1,163, the current price target is an average from 2 analysts. New target price is 14% below last closing price of Rp980. Stock is up 22% over the past year. The company is forecast to post earnings per share of US$0.00069 for next year compared to US$0.00028 last year. Reported Earnings • May 03
First quarter 2024 earnings released: EPS: US$0 (vs US$0 in 1Q 2023) First quarter 2024 results: EPS: US$0 (in line with 1Q 2023). Revenue: US$618.6m (down 4.9% from 1Q 2023). Net income: US$8.86m (down 62% from 1Q 2023). Profit margin: 1.4% (down from 3.6% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 3.2% growth forecast for the Chemicals industry in Indonesia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance. Reported Earnings • Mar 30
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: EPS: US$0 (in line with FY 2022). Revenue: US$2.76b (down 6.8% from FY 2022). Net income: US$26.1m (up US$24.4m from FY 2022). Profit margin: 0.9% (up from 0.1% in FY 2022). The increase in margin was driven by lower expenses. Revenue exceeded analyst estimates by 7.6%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 2.9% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in Asia. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has remained flat, which means it is well ahead of earnings. New Risk • Dec 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indonesian stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Share price has been highly volatile over the past 3 months (14% average weekly change). New Risk • Nov 03
New major risk - Revenue and earnings growth Earnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Earnings have declined by 15% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). Reported Earnings • Nov 02
Third quarter 2023 earnings released: EPS: US$0 (vs US$0 in 3Q 2022) Third quarter 2023 results: EPS: US$0 (in line with 3Q 2022). Revenue: US$738.1m (down 2.8% from 3Q 2022). Net income: US$5.48m (up 123% from 3Q 2022). Profit margin: 0.7% (up from 0.3% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Chemicals industry in Indonesia. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Recent Insider Transactions • Oct 31
President Commissioner recently bought Rp5.7b worth of stock On the 25th of October, Prajogo Pangestu bought around 6m shares on-market at roughly Rp1,030 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth Rp13b. Insiders have collectively bought Rp36b more in shares than they have sold in the last 12 months. Price Target Changed • Aug 24
Price target decreased by 11% to Rp800 Down from Rp896, the current price target is provided by 1 analyst. New target price is 20% below last closing price of Rp1,000. Stock is up 18% over the past year. The company is forecast to post earnings per share of US$0.00085 for next year compared to US$0.000018 last year. Reported Earnings • Aug 02
Second quarter 2023 earnings released: EPS: US$0 (vs US$0 in 2Q 2022) Second quarter 2023 results: EPS: US$0 (in line with 2Q 2022). Revenue: US$723.5m (down 10.0% from 2Q 2022). Net income: US$7.08m (up US$7.59m from 2Q 2022). Profit margin: 1.0% (up from net loss in 2Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Reported Earnings • Jun 21
First quarter 2023 earnings released First quarter 2023 results: Revenue: US$650.7m (down 20% from 1Q 2022). Net income: US$23.3m (up 149% from 1Q 2022). Profit margin: 3.6% (up from 1.1% in 1Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 15% per year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 02
Second quarter 2022 earnings released: EPS: US$0 (vs US$0.001 in 2Q 2021) Second quarter 2022 results: EPS: US$0 (down from US$0.001 in 2Q 2021). Revenue: US$804.3m (down 3.0% from 2Q 2021). Net loss: US$509.0k (down 101% from profit in 2Q 2021). Revenue is expected to fall by 3.7% p.a. on average during the next 3 years compared to a 1.9% decline forecast for the Chemicals industry in Indonesia. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jul 12
Investor sentiment improved over the past week After last week's 15% share price gain to Rp820, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 13x in the Chemicals industry in Asia. Total returns to shareholders of 15% over the past three years. Board Change • Apr 27
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 2 experienced directors. 2 highly experienced directors. 1 independent director (3 non-independent directors). President Commissioner Prajogo Pangestu is the most experienced director on the board, commencing their role in 1993. Independent Commissioner Henky Susanto was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Price Target Changed • Apr 13
Price target decreased to Rp984 Down from Rp1,061, the current price target is an average from 4 analysts. New target price is 12% above last closing price of Rp875. Stock is down 10% over the past year. The company is forecast to post earnings per share of US$0.0021 for next year compared to US$0.0012 last year. Reported Earnings • Apr 06
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: EPS: US$0.001 (up from US$0 in FY 2020). Revenue: US$3.16b (up 35% from FY 2020). Net income: US$109.1m (up 201% from FY 2020). Profit margin: 3.5% (up from 1.6% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 3.1%, compared to a 27% growth forecast for the industry in Indonesia. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 10
Investor sentiment improved over the past week After last week's 19% share price gain to Rp1,060, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 15x in the Chemicals industry in Asia. Total returns to shareholders of 97% over the past three years. Valuation Update With 7 Day Price Move • Jul 30
Investor sentiment improved over the past week After last week's 18% share price gain to US$955, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 16x in the Chemicals industry in Asia. Total returns to shareholders of 167% over the past three years. Reported Earnings • Apr 04
Full year 2020 earnings released The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: US$2.33b (down 2.8% from FY 2019). Net income: US$36.3m (down 18% from FY 2019). Profit margin: 1.6% (down from 1.8% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 102 percentage points per year, which is a significant difference in performance. Is New 90 Day High Low • Dec 08
New 90-day high: Rp1,220 The company is up 53% from its price of Rp800 on 09 September 2020. The Indonesian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 37% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is Rp167 per share. Price Target Changed • Nov 18
Price target raised to Rp852 Up from Rp755, the current price target is an average from 3 analysts. The new target price is 11% below the current share price of Rp960. As of last close, the stock is down 18% over the past year. Is New 90 Day High Low • Nov 10
New 90-day high: Rp970 The company is up 5.0% from its price of Rp925 on 12 August 2020. The Indonesian market is up 2.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is Rp17.49 per share. Is New 90 Day High Low • Sep 21
New 90-day low: Rp700 The company is down 41% from its price of Rp1,185 on 23 June 2020. The Indonesian market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is down 17% over the same period.